A telephone survey led by University of Wisconsin-Madison researchers this summer found that proportionally more scientists than laypeople are worried about some risks of nanotechnology. The study is to be published in Nature Nanotechnology....
The global market for stem-cell therapies, diagnostics, and other products could top $10 billion by 2016, which ...
Angel investing often is the first money coming into a young company, and although it is a large segment of overall venture capital, it hasn't been tracked as closely. That's beginning to change, according to columnist Michael Rosen, and in this edition of Yer Biotech...
Centrose, LLC and the University of Wisconsin-Madison have received an additional $150,000 in funding from the National Science Foundation to fund a joint effort aimed at lowering the toxic affects and increasing the potency of cancer-fighting drugs. ...
Scientific teams in Wisconsin and Japan have developed an ethically uncomplicated method of turning human skin cells into cells that behave like embryonic stem cells. The development, described by stem cell researcher Jamie Thomson as a game-changing event, could have significant scientific and political fallout...
A well-drafted license agreement can be crucial to a start-up firm's successful exploitation of technology, says Madison attorney Joe Boucher. In this edition of Early Stage, Boucher notes that the significance of a license agreement extends beyond the licensor and licensee because it may be...
Cambridge Major Laboratories continues on its expansion track with the acquisition of ChemShop B.V. of Weert Netherlands. The newly combined organization becomes one of the largest global suppliers of active pharmaceutical ingredient services. ...
Wisconsin's entrepreneurial and investment climate was the focus of the 2007 Early-Stage Symposium in Madison, but amid the investment pitches and the talk of what Wisconsin is doing right, there are some real concerns about how Wisconsin stacks up against other states. In particular, entrepreneurs...
Just as Wisconsin is gaining some traction in the venture capital chase, a federal bill threatens to make the state less attractive to private-equity investors, particularly from outside Wisconsin, opines columnist Tom Still. In this edition of Inside Wisconsin, Still notes that the bill is...
The present looks good but the future is more of a mystery to Wisconsin biotechnology executives, according to the first quarterly survey of the biotech and medical device industry. The survey, conducted by the Wisconsin Biotechnology and Medical Device Association and the state Department of...